Ginkgo Memory Meta-analysis: What the Evidence Says

Quick Answer

Ginkgo Memory Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• After 12 months,therapy was associated with reduced amyloid ß-protein oligomerisation a well as preserved cognition and improved daily functioning. [Feng Jing-Xuan (2026); evidence level 1]
• However, their clinical significance remains uncertain, and certainty of evidence is overall low due to significant heterogeneity. [Feng Jing-Xuan (2026); evidence level 1]
• It should be emphasized that ARCD denotes a physiological decline in cognitive function associated with advancing age; its severity does not meet the diagnostic threshold for mild cognitive impairment (MCI), which represents a transitional state between normal aging and dementia. [Feng Xueyan (2026); evidence level 1]
• However, current pharmacological treatments, such as cholinesterase inhibitors, have limited efficacy and are associated with side effects. [Feng Xueyan (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For ginkgo memory meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Feng Jing-Xuan (2026). Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction—meta-analysis of pooled data from randomised clinical trials. DOI: 10.3389/fneur.2025.1658064. PMCID: PMC13023401. PMID: 41908799. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13023401/
• Feng Xueyan (2026). The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis of randomized controlled trials. DOI: 10.3389/fphar.2025.1672171. PMCID: PMC12864429. PMID: 41640686. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12864429/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.